A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed POEMS syndrome

Key Findings

• ●Complete hematologic response 46%, neurologic response 95%
• ●VEGF response 83%, median time to response 2 months
• ●3-year OS 90%, 3-year PFS 75%
• ●No treatment-related deaths or grade 3+ lenalidomide adverse events

Referenced in (1 disease)

1. passsource metadataJun 1, 2026, 04:40 PMby pubmed-api

   Stored DOI was incorrect; corrected to the PubMed-registered DOI (verified to resolve to this article).

   tools: pubmed.esummary, crossref.works